Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atropine Clear all
Completed Phase 4 Interventional

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

NCT05065424
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 72 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jun 10, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

NCT06366087
View directory record Official record
Conditions
Atropine Bioequivalence
Interventions
Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jun 10, 2026, 4:20 PM EDT
Completed Phase 4 Interventional

Trial Comparing Daily Atropine Versus Weekend Atropine

NCT00094614
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 7 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Jun 10, 2026, 4:20 PM EDT
Not listed Phase 2 Interventional

Low Dose Atropine for Symptomatic Vitreous Floaters

NCT06174935
View directory record Official record
Conditions
Vitreous Floaters
Interventions
0.01% atropine ophthalmic drop
Drug
Lead sponsor
Jeanette Du
Other
Eligibility
19 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Reston, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Jun 10, 2026, 4:20 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Response to Atropine Drops (RAD) Study

NCT05199597
View directory record Official record
Conditions
Myopia
Interventions
0.01% atropine, 0.05% atropine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Jun 10, 2026, 4:20 PM EDT
Not listed Phase 2 Interventional

StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study

NCT02082054
View directory record Official record
Conditions
Rhinitis, Seasonal, Allergic
Interventions
PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg, PSE 120 mg, CM 8 mg, Atropine 0.24 mg
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Stockbridge, Georgia • Louisville, Kentucky • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Jun 10, 2026, 4:20 PM EDT
Recruiting Phase 2 Interventional

Myopia Control: a Comparison Study Between Atropine and MiSight

NCT05815784
View directory record Official record
Conditions
Myopia
Interventions
Atropine, MiSight contact lenses
Drug · Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
5 Years to 12 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jun 10, 2026, 4:20 PM EDT
Terminated Phase 4 Interventional Results available

Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation

NCT03750656
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
Hyoscyamine, Tamsulosin
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jun 10, 2026, 4:20 PM EDT
Recruiting Phase 4 Interventional

APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes

NCT07434635
View directory record Official record
Conditions
Eye Disorders
Interventions
Atropine 1%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 10, 2026, 4:20 PM EDT
Terminated Phase 3 Interventional Results available

Combined Patching-Atropine for Residual Amblyopia

NCT00506675
View directory record Official record
Conditions
Amblyopia
Interventions
Patching, Atropine
Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 9 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jun 10, 2026, 4:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effects of Low Dose Atropine on Choroidal Thickness

NCT03544827
View directory record Official record
Conditions
Myopia
Interventions
Atropine
Drug
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years to 35 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jun 10, 2026, 4:20 PM EDT
Recruiting Phase 3 Interventional

A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control

NCT07095894
View directory record Official record
Conditions
Myopia
Interventions
Atropine, Spectacles with HAL, Placebo Eyedrops
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
5 Years to 11 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Fullerton, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 4:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Influence of Atropine on Choroidal Thickness

NCT03158142
View directory record Official record
Conditions
Myopia
Interventions
Atropine Sulfate 1% Oph Soln
Drug
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Jun 10, 2026, 4:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adverse Events Related to Low Dose Atropine

NCT05683535
View directory record Official record
Conditions
Myopia, Progressive
Interventions
Atropine Sulfate
Drug
Lead sponsor
Scripps Health
Other
Eligibility
Not listed
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Jun 10, 2026, 4:20 PM EDT
Terminated Not applicable Interventional Results available

Safety and Accuracy of Regadenoson-Atropine Stress Echocardiography in CAD

NCT00894179
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
regadenoson and atropine
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 4:20 PM EDT
Completed Phase 3 Interventional

Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

NCT00000170
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Eye Patch
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Jun 10, 2026, 4:20 PM EDT
Completed Phase 3 Interventional

Amblyopia (Lazy Eye) Treatment Study

NCT00001864
View directory record Official record
Conditions
Amblyopia, Anisometropia, Strabismus
Interventions
Atropine, Patch
Drug · Device
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old

NCT00944710
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Plano lens
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 7 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Fullerton, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Jun 10, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds

NCT00315328
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Patching, Near activities
Drug · Device · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 12 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Jun 10, 2026, 4:20 PM EDT
Terminated Phase 3 Interventional

Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

NCT03942419
View directory record Official record
Conditions
Myopia
Interventions
Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
3 Years to 12 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Birmingham, Alabama • Glendale, Arizona • Azusa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Jun 10, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Analysis of Atropine and Propranolol Induced Changes

NCT00251602
View directory record Official record
Conditions
Healthy
Interventions
Atropine, Propranolol, Normal Saline
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2012 · Synced Jun 10, 2026, 4:20 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Changes in Eye Shape With Myopia Management Interventions

NCT06450132
View directory record Official record
Conditions
Myopia
Interventions
Atropine Ophthalmic, MiSight 1-day disposable contact lenses
Drug · Device
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 30 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jun 10, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old

NCT00315302
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Plano Lens
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 6 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Fullerton, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Jun 10, 2026, 4:20 PM EDT
Completed Early Phase 1 Interventional

Pharmacokinetics of Atropine Oral Gel

NCT05164367
View directory record Official record
Conditions
Cerebral Palsy, Sialorrhea
Interventions
Atropine sulfate gel (0.01%)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Jun 10, 2026, 4:20 PM EDT